Sign in
Taking people in United StatesPhase 2

Exercise and nicotinamide riboside to improve muscle and fitness after blood cell transplant

Tests exercise training with nicotinamide riboside in young transplant survivors, looking at muscle strength.

Key facts

Who runs it
Children's Hospital of Philadelphia
Where
Duarte, Memphis, and Philadelphia, United StatesSee the 3 sites
Trial code
Registry title
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Status
Recruiting
Phase
Phase 2
People taking part
80 people, planned
Started
23 Feb 2023
Planned end
30 Jun 2026
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Nicotinamide Riboside
  • Placebo
  • Exercise Intervention
Record updated
4 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for teenagers and young adults aged 10-30 who had a donor blood stem cell transplant for leukemia, aplastic anemia, bone marrow failure or myelodysplastic syndrome. It tests exercise training and an NR supplement on muscle and fitness.

Age
10-30 years
Sex
Males and females can join.
Disease stage
Leukemia (myeloid or lymphoid), aplastic anemia, bone marrow failure syndrome or myelodysplastic syndrome that needed a donor (allogeneic) transplant. 6-48 months after the transplant.
Earlier treatment
Must have had a donor (allogeneic) hematopoietic cell transplant 6-48 months ago. Must not have used NAD+ precursors (high doses) within 4 weeks or another investigational drug within 4 weeks.

Main reasons for not taking part

  • Active cancer, or high-dose steroids at the baseline visit
  • Already meeting public health exercise guidelines
  • Known sensitivity to NR, or medicines such as statins that raise the risk of NR toxicity
  • Kidney disease, liver disease, or insulin-treated diabetes
  • Pregnant or planning pregnancy, or heart, lung or other conditions that make exercise unsafe

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Males and females, ages 10-30 years at enrollment
  • Able to understand and speak English
  • Diagnosis of leukemia (myeloid, lymphoid), aplastic anemia, bone marrow failure syndrome, or myelodysplastic syndrome requiring allogeneic HCT
  • 6-48 months from allogeneic HCT
  • Females must have a negative urine/serum pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study
  • Subject's informed consent or parental/guardian permission (informed consent) and if appropriate, child assent
  • Minimum weight of 24 kg

Who cannot take part

  • Concurrent use of any medications, including statins, likely to increase risk of NR toxicity
  • Active malignancy, investigational agent(s) within 4 wks, or supraphysiological glucocorticoids at the baseline visit
  • Diabetes Mellitus requiring insulin or insulin secretagogue
  • Unstable angina or history of acute myocardial infarction (<5 days of planned study procedures)
  • Uncontrolled arrhythmia causing symptoms
  • Thrombosis of lower extremities
  • Non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (e.g. infection, renal failure, thyrotoxicosis, >moderate Graft versus host disease (GVHD) resulting in physical or functional impairment)
  • Hemoglobin < 10 g/dL
  • Platelets < 50K
  • HbA1C ≥ 8% or fasting glucose > 125 mg/dL; However if the participant is diabetic, both fasting glucose level and HbA1C must meet the criteria to be deemed eligible
  • Kidney disease (eGFR < 60 ml/min/1.73 m2)
  • Liver disease Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) (ALT/AST > 3 x ULN)
  • Known sensitivity to NR
  • Currently meeting public health exercise guidelines
  • Use of NAD+ precursors (supra-physiologic) within 4 weeks
  • Limitations in physical function preventing exercise testing/training
  • Recurrent syncope
  • Symptomatic severe aortic stenosis
  • Pulmonary embolus <3 months of study procedures
  • Symptomatic moderate or severe persistent asthma based on Forced Expiratory Volume (FEV) from pre-HCT pulmonary function testing
  • Room air desaturation at rest ≤85%
  • Females: Pregnant or planning pregnancy
  • Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures
  • For MRI procedure: Contraindications to MRI. Individuals will be screened to ensure they can safely complete the MRI. *participants who cannot complete the MRI will not be excluded from participation in the remainder of the study procedures if they meet those inclusion and exclusion criteria
  • Current weight precludes safe completion of study procedures

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 10 and 30 years old?

Where in United States

  • City of Hope Medical CenterDuarte, United StatesContact: Lanie Lindenfeld, MA, CCRPTaking people
  • St. Jude Children's Research HospitalMemphis, United StatesContact: Sarah Terrell, MSTaking people
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Susan LeeTaking people

About the trial

What the trial wants to find out

This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors.

Read full original descriptionShow less

The primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 weeks. Key secondary outcomes are the change in muscle strength (ankle plantarflexion) from baseline to 16 weeks, the change in grip strength from baseline to 16 weeks, the change in lower extremity muscle mass from baseline to 16 weeks, the change in muscle OXPHOS capacity from baseline to 16 weeks, and the change in aerobic capacity (VO2 max) from baseline to 16 weeks.

The 4 groups in the trial

  • Nicotinamide Riboside (NR)Treatment being tested

    Investigators will use Good Manufacturing Process (GMP)-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA). Investigators dose based on body weight, and monitor for adverse effects (AEs). For individuals with weight \> 72 kg: 900 mg po qd x 16 wks. For individuals with weight \> 48 kg and ≤ 72 kg: 600 mg po qd x 16 wks. For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 16 wks.

    Treatment: Nicotinamide Riboside

  • PlaceboPlacebo, for comparison

    Matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule). Doses of placebo will match the body weight schema for dosing of NR. Investigators dose based on body weight, and monitor for adverse effects (AEs). For individuals with weight \> 72 kg: 900 mg po qd x 16 wks. For individuals with weight \> 48 kg and ≤ 72 kg: 600 mg po qd x 16 wks. For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 16 wks.

  • Exercise Intervention and NRTreatment being tested

    The exercise program consists of at-home training sessions including: aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strength training exercises. Participants in this arm will receive both the Exercise Intervention and the NR.

    Treatment: Nicotinamide Riboside and Exercise Intervention

  • Exercise Intervention and PlaceboTreatment being tested

    The exercise program consists of at-home training sessions including: aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strength training exercises. Participants in this arm will receive both the Exercise Intervention and the Placebo

    Treatment: Placebo and Exercise Intervention

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Intensive Tailored Exercise Training With NAD+ Precursor Supplementation to Improve Muscle Mass and Fitness in Adolescent and Young Adult Hematopoietic Cell Transplant Survivors
Plain-language title
Exercise and nicotinamide riboside to improve muscle and fitness after blood cell transplantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05194397, who can take part
Record updated
4 December 2025